ZLAB (Zai Lab) Payments of Debt: $-183.5 Mil (TTM As of Mar. 2026)


ZLAB Zai Lab Ltd ZLAB
64 GF Score
Price $18.52
GF Value $30.30
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Zai Lab Payments of Debt?

Zai Lab ZLAB +0.76% 64 Payments of Debt is $-183.5 Mil as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.30 (Possible Value Trap). The stock has 8 warning signs investors should review.

Zai Lab's Payments of Debt for the three months ended in Mar. 2026 was $-105.5 Mil.

Zai Lab's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-183.5 Mil.

Zai Lab Payments of Debt Related Terms

Zai Lab Payments of Debt Historical Data

* Premium members only.

The historical data trend for Zai Lab's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zai Lab Payments of Debt Chart

Zai Lab Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.28 -138.89

Zai Lab Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -60.90 -21.91 -34.12 -21.95 -105.50
ZLAB
64GF Score
Zai Lab Ltd ZLAB
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zai Lab Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-183.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-183.5 Mil mean?
Zai Lab (ZLAB) has a Payments of Debt of $-183.5 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Zai Lab and its competitors.
Is Zai Lab's Payments of Debt too high?
Zai Lab's current Payments of Debt is $-183.5 Mil. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's Payments of Debt compare to TYRA and TRVI?
Zai Lab's Payments of Debt of $-183.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Zai Lab and its competitors. Zai Lab's current Payments of Debt is $-183.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.30, compared to a current price of $18.52 — trading 38.9% below its estimated fair value. The current Payments of Debt is $-183.5 Mil. Zai Lab's overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Zai Lab (ZLAB), the current Payments of Debt is $-183.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zai Lab (ZLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued. The current stock price of $18.52 is trading 38.9% below its estimated GF Value™ of $30.30. GuruFocus considers Zai Lab to be Possible Value Trap.

Key valuation signals for ZLAB:

  • Payments of Debt: $-183.5 Mil
  • GF Value™: $30.30 vs. price of $18.52 (38.9% below fair value)
  • GF Score™: 64/100 with 8 warning signs

No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zai Lab Business Description

Other Exchanges 09688:Hong Kong1ZLB:Germany
Address 899 Halei Road, Building B, Pudong, Shanghai, CHN, 201203
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score

Get the complete analysis for ZLAB

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.52
Price
$30.30
GF Value